A recent study showed that ACSS2 contributes to myeloma progression in obese patients and an ACSS2 inhibitor can reduce the growth of myeloma in vitro and in diet induced obese mouse models (Li et al., 2021). Here, ACSS2 is linked to plasma cell myeloma.